Dr. Ilene C. Weitz is an Associate Professor of Clinical Medicine at the Keck School of Medicine at the University of Southern California (USC). Her practice sites include, LAC+USC Medical Center, Keck Hospital of USC and USC Norris Cancer Hospital. Dr. Weitz is board certified in Internal Medicine and Hematology.
Ellen K. Ritchie, MD is assistant professor of medicine and a member of the Leukemia Program at the Weill Cornell Medical College of Cornell University and the New York Presbyterian Hospital in New York City.
Dr. Podoltsev practice is focused on myeloid neoplasms including acute myelogenous leukemias (AML), myelodisplastic syndromes (MDS), myeloproliferative neoplasms (MPNs) like polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF), chronic myelogenous leukemia (CML) among others. He is providing care for patients with
AAMDSIF hosted the 2020 National Patient & Family Conference ONLINE over three days, July 17 - 19, 2020. The Conference featured three days of educational workshops, panels and speakers for patients, families and caregivers with
This study is evaluating the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of multiple intravenous (IV) doses of ALXN1210 administered to participants with PNH who have not previously been treated with complement inhibitor.
This is a Phase I/II, first-in-human study consisting of four sequential parts and an open-label extension (OLE). The safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single doses of RO7112689 will be evaluated in healthy volunteers (HV) during part 1. The safety, tolerability, PK and PD of multiple doses of RO7112689 will be evaluated in participants with
Due to the coronavirus (COVID-19) pandemic, AAMDSIF made the decision to move our conferences online in order to protect the health of our patients, families, caregivers and faculty.
We would like to acknowledge the support of our many generous patients, families and caregivers as well as our corporate partners including Celgene, Alexion, Novartis, Genentech, Jazz Pharmaceuticals, Apellis and Acceleron.